📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-17 08:55
510 analysed today
510
Today
133,399
All-time analysed
40,108
Positive
6,279
Negative
79,197
Neutral
7,747
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
10 announcements match the current filters (relevance ≥ 5).
Veerhealth Care Q1 Revenue Surges 388% YoY to Rs 25.09 Cr; FY27 Target at Rs 105 Cr
Veerhealth Care reported a 388.13% YoY surge in Q1FY27 total revenue to Rs 25.09 crore, with net profit rising 412.50% YoY to Rs 1.23 crore. The company highlighted major order wins in FY27, including Rs 32.93 crore from a New York-based firm and Rs 18.24 crore from a domestic FMCG firm. Management issued strong guidance targeting Rs 105 crore in total income with Rs 5-6 crore PAT for FY27, and Rs 156 crore total income for FY28. Growth is supported by a newly commenced manufacturing facility and USFDA plant clearance for OTC exports.
Confidence: HIGH
What changedThe company reported record quarterly revenue of Rs 25.09 crore, commissioned its new manufacturing facility, and set an aggressive FY27 revenue target of Rs 105 crore.
Why it mattersThe FY27 target of Rs 105 crore is nearly double its TTM revenue (~Rs 53 crore), driven by export expansion following USFDA OTC plant clearance and new production lines.
Q1FY27 Revenue: ₹ 25.09 CroreQ1FY27 PAT: ₹ 1.23 CroreNY Order Value: ₹ 3293 LakhsFY27 Revenue Guidance: ₹ 105 croresFY27 Target vs TTM Revenue: ~198%
📅 Short termStrong operational momentum and sizeable order pipeline are likely to support near-term sentiment.
📈 Long termSuccessful scale-up in US and international OTC markets along with backward integration could significantly enhance operational scale over FY27-FY28.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution and delivery risk on large export contracts
- Aggressive guidance vs historical revenue scale
- Promoter shareholding is relatively low at 31.5%
Key Highlights
Q1FY27 total revenue rose 388.13% YoY to Rs 25.09 crore, with PAT up 412.50% YoY to Rs 1.23 crore.
EBITDA increased 233.87% YoY to Rs 2.07 crore, though EBITDA margin contracted 381 bps YoY to 8.25%.
Secured sizeable order wins in FY27, including Rs 32.93 crore from New York and Rs 18.24 crore from an Indian FMCG player.
Management guided FY27 revenue of Rs 105 crore (PAT Rs 5-6 crore) and FY28 revenue of Rs 156 crore (PAT Rs 9-10 crore).
👀 What to Watch
Track quarterly order fulfillment rates, margin expansion, and progress toward meeting the guided Rs 105 crore annual top-line target.
Veerhealth Care Q1 PAT Jumps to ₹1.23 Cr; Revenue Up 455% YoY; New CS Appointed
Veerhealth Care reported a massive surge in Q1 FY27 (June 2026) revenue to ₹24.93 Cr, a 455% increase compared to ₹4.49 Cr in the same quarter last year. The company turned profitable with a net profit of ₹1.23 Cr, recovering from a loss of ₹0.35 Cr in the preceding March 2026 quarter. Additionally, the company has received ₹4.87 Cr as part payment for 1 crore warrants issued at ₹20.25 each. The board also appointed Ruchi Shah, daughter of the Chairperson, as the new Company Secretary following the resignation of Ashita Chittora.
Confidence: HIGH
What changedThe company achieved a significant scale-up in quarterly revenue and profitability while transitioning its compliance leadership to a promoter-related individual.
Why it mattersThe financial performance indicates a potential structural shift in business volume, as Q1 revenue alone is nearly 77% of the entire previous financial year's revenue. The warrant fundraise provides growth capital but introduces dilution risks.
Q1 FY27 Revenue: ₹24.93 CrQ1 FY27 PAT: ₹1.23 CrQ1 Revenue vs TTM Revenue: 77.9%Warrant Funds Received: ₹4.87 CrWarrant Issue Price: ₹20.25
📅 Short termThe stock is likely to react positively to the strong earnings turnaround and massive YoY revenue growth.
📈 Long termIf the company sustains this new quarterly revenue run-rate, it could lead to a significant re-rating, though the high P/E and promoter-related management appointment warrant caution.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Related-party appointment (CS is daughter of Chairperson)
- Equity dilution from 1 crore warrants
- High P/E ratio of 173.6
Key Highlights
Revenue from operations grew 455.7% YoY to ₹24.93 Cr in Q1 FY27.
Net profit stood at ₹1.23 Cr for the quarter, compared to ₹0.24 Cr in Q1 FY26.
Received ₹4.87 Cr towards 1,00,00,000 warrants convertible at ₹20.25 per share.
Basic EPS improved to ₹0.61 from ₹0.12 YoY and a negative ₹0.18 in the previous quarter.
New CS Ruchi Shah appointed, who is the daughter of Chairperson Mr. Yogesh Shah.
👀 What to Watch
Investors should monitor if the sharp revenue spike in Q1 (which represents ~77% of total FY26 revenue) is sustainable or due to a one-off bulk order. Watch for the full conversion of warrants and the resulting equity dilution.
Veerhealth Care Q1 Revenue Surges 455% to ₹24.93 Cr; Appoints New CS
Veerhealth Care reported a massive scale-up in Q1 FY27, with revenue jumping to ₹24.93 Cr from ₹4.49 Cr in the same quarter last year. Net profit followed suit, rising to ₹1.23 Cr compared to ₹0.24 Cr YoY. The company also announced the appointment of Ms. Ruchi Shah as Company Secretary, noting she is the daughter of the Chairperson. Furthermore, the company has received ₹4.87 Cr as part-payment for a ₹20.25 Cr warrant issuance, indicating significant upcoming capital infusion.
Confidence: HIGH
What changedThe company has significantly scaled its quarterly revenue and replaced its Company Secretary with a related-party appointee.
Why it mattersThe financial performance suggests a major shift in business volume (Q1 revenue is ~77% of total FY26 revenue). The warrant issuance of ₹20.25 Cr is substantial compared to the current market cap of ₹94 Cr.
Q1 FY27 Revenue: ₹24.93 CrQ1 FY26 Revenue: ₹4.49 CrQ1 Revenue vs TTM Revenue: 77.9%Warrant Issue Size: ₹20.25 CrWarrant Price: ₹20.25
📅 Short termThe stock is likely to react positively to the strong earnings growth and the progress on the warrant-based fundraise.
📈 Long termIf the company maintains this new revenue run-rate, it represents a structural re-rating; however, warrant conversion will dilute existing shareholders.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Related-party appointment (New CS is Chairperson's daughter)
- Significant equity dilution from 1 crore warrants
- Sustainability of the sudden revenue spike
Key Highlights
Revenue from operations grew 455% YoY to ₹24.93 Cr for the quarter ended June 30, 2026
Net profit increased to ₹1.23 Cr in Q1 FY27 from ₹0.24 Cr in Q1 FY26
Received ₹4.87 Cr towards the issuance of 1,00,00,000 warrants priced at ₹20.25 each
Appointed Ms. Ruchi Shah as CS and Compliance Officer, effective August 13, 2026
Annual General Meeting (AGM) scheduled for September 23, 2026
👀 What to Watch
Investors should monitor if the sharp revenue jump in Q1 is sustainable or driven by one-off orders, and track the conversion of warrants which will lead to equity dilution.
₹24.93 Cr Revenue: Veerhealth Care Reports 455% YoY Growth in Q1 FY27
Veerhealth Care reported a massive surge in Q1 FY27 revenue to ₹24.93 cr, a 455% increase from ₹4.49 cr in the same quarter last year. Net profit rose to ₹1.23 cr compared to ₹0.24 cr YoY, marking a sharp recovery from the ₹0.35 cr loss in the preceding March 2026 quarter. The company also confirmed receiving ₹4.87 cr as part payment for a ₹20.25 cr warrant issue. Additionally, the Board appointed Ruchi Shah, daughter of the Chairperson, as the new Company Secretary following the resignation of the incumbent.
Confidence: HIGH
What changedThe company delivered record quarterly revenue and profit, significantly exceeding its historical quarterly averages and turning around from a loss in the previous quarter.
Why it mattersThe scale of operations has shifted dramatically; Q1 FY27 revenue alone represents approximately 77% of the entire FY26 annual revenue (₹32.48 cr), suggesting a potential structural change in business volume.
Revenue (Q1 FY27): ₹24.93 crNet Profit (Q1 FY27): ₹1.23 crQ1 Revenue vs FY26 Total Revenue: 76.7%Warrant Issue Total Value: ₹20.25 crWarrant Funds Received to date: ₹4.87 cr
📅 Short termThe stock is likely to react positively to the significant top-line and bottom-line growth and the successful turnaround from the previous quarter's loss.
📈 Long termIf the company maintains this new scale of operations, it could lead to a significant re-rating, though the low promoter holding (31.5%) and high P/E remain key monitoring points.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Related-party appointment (New CS is daughter of Chairperson)
- Low promoter holding at 31.5%
- Potential equity dilution from 1 crore warrant conversions
Key Highlights
Revenue from operations grew 455% YoY to ₹24.93 cr from ₹4.49 cr.
Net profit increased to ₹1.23 cr from ₹0.24 cr in the year-ago period.
Quarterly EPS improved to ₹0.61 from ₹0.12 in June 2025.
Received ₹4.87 cr towards the issuance of 1,00,00,000 warrants priced at ₹20.25 each.
Total expenses rose to ₹23.61 cr, largely driven by stock-in-trade purchases of ₹25.51 cr.
👀 What to Watch
Investors should monitor if this high revenue run-rate is sustainable or driven by one-off bulk orders, and track the conversion of warrants which will lead to equity dilution.
Veerhealth Care Q1 Revenue Jumps 455% to ₹24.93 Cr; PAT at ₹1.23 Cr
Veerhealth Care reported a massive surge in Q1 FY27 performance, with revenue reaching ₹24.93 cr compared to ₹4.49 cr in Q1 FY26. Net profit for the quarter stood at ₹1.23 cr, a significant turnaround from the ₹0.35 cr loss in the preceding March quarter. The company also confirmed receiving ₹4.87 cr as part payment for 1 crore warrants issued at ₹20.25 each. Additionally, a new Company Secretary, who is a related party to the Chairperson, has been appointed.
Confidence: HIGH
What changedThe company reported a significant scale-up in quarterly operations and replaced its Company Secretary with a related party (Chairperson's daughter).
Why it mattersThe Q1 revenue of ₹24.93 cr represents nearly 78% of the entire TTM revenue, indicating a major shift in business scale or order execution. The warrant funding provides necessary capital for a company with a small net worth of ₹23 cr.
Q1 FY27 Revenue: ₹24.93 crQ1 FY27 Net Profit: ₹1.23 crQ1 Revenue vs TTM Revenue: 77.9%Warrant Issue Price: ₹20.25Funds Received for Warrants: ₹4.87 cr
📅 Short termThe stock is likely to react positively to the strong earnings turnaround and the substantial YoY growth in both top and bottom lines.
📈 Long termIf the company can maintain this new baseline of revenue and successfully deploy warrant capital, it could lead to a structural re-rating, though the high P/E remains a factor.
⚠ Risk flags
- Related-party appointment (New CS is Chairperson's daughter)
- High P/E ratio of 173.6
- Small-cap volatility
Key Highlights
Revenue from operations increased by 455% YoY to ₹24.93 cr in Q1 FY27.
Net profit rose to ₹1.23 cr in Q1 FY27 from ₹0.24 cr in the same quarter last year.
Basic EPS improved to ₹0.61 from ₹0.12 YoY.
Received ₹4.87 cr towards the issuance of 1,00,00,000 warrants priced at ₹20.25 each.
34th Annual General Meeting scheduled for September 23, 2026.
👀 What to Watch
Investors should monitor if this sharp revenue growth is sustainable across future quarters and track the utilization of the ₹20.25 cr warrant proceeds for business expansion.
₹5.27 Cr Repeat Order from Leading FMCG Group; FY27 Revenue Target Set at ₹105 Cr
Veerhealth Care has secured a repeat monthly order worth ₹5.27 Crores from a prominent 125-year-old Indian FMCG group for face care products. This single order represents approximately 16.5% of the company's TTM revenue and is scheduled for execution within 45 days. Additionally, the company has entered the Sudan market with a ₹15.74 lakh sample order for Gripe Water. Management has issued aggressive guidance, targeting ₹105 Crores in revenue for FY27, which would be a 223% increase over FY26 revenue of ₹32.48 Crores.
Confidence: HIGH
What changedThe company secured a significant repeat order from a major domestic client and provided high-growth financial guidance for the next two fiscal years.
Why it mattersFor a micro-cap company with ₹32 Cr in TTM revenue, a ₹5.27 Cr monthly repeat order is highly material, validating its manufacturing capabilities for large FMCG players and supporting a potential multi-year growth trajectory.
Order Value: ₹5.27 CrOrder vs TTM Revenue: ~16.5%FY27 Revenue Guidance: ₹105 CrFY26 Revenue: ₹32.48 CrExecution Timeline: 45 days
📅 Short termThe stock may see positive momentum due to the materiality of the order and the aggressive forward-looking guidance provided by management.
📈 Long termIf the company achieves its FY27 and FY28 targets (₹105 Cr and ₹156 Cr respectively), it would represent a significant structural scale-up from its current base, though execution risk remains high given the current low margins.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Aggressive growth targets (3x revenue in one year)
- High P/E valuation of 161.6
- Relatively low promoter holding at 31.5%
Key Highlights
Received a repeat monthly order worth ₹5.27 Crores for face care products from a major FMCG client.
Order execution timeline is set for within 45 days.
Management projects FY27 total income of ₹105 Crores with a PAT of ₹5-6 Crores.
Secured first export sample order from Sudan worth ₹15.74 lakhs.
Company is in advanced talks with a large Indo-Canadian hotel amenities supplier.
👀 What to Watch
Investors should monitor the quarterly revenue run-rate to see if it aligns with the ambitious ₹105 Cr annual target. Key execution milestones include the successful delivery of the current ₹5.27 Cr order and the conversion of 'advanced talks' with the hotel amenities supplier into firm contracts.
₹5.27 Cr Skincare Order from Large FMCG Company to be Executed in 45 Days
Veerhealth Care has secured a domestic order worth ₹526.84 Lakhs (₹5.27 Cr) for the supply of face care products to a major Indian FMCG company. This single order is highly material, representing approximately 16.5% of the company's total FY26 revenue of ₹32.48 Cr. The contract requires rapid execution within a 45-day window, which is expected to significantly impact the immediate quarterly turnover. While the client's identity is withheld due to confidentiality, the scale of the win is substantial for a micro-cap company with an ₹84 Cr market valuation.
Confidence: HIGH
What changedThe company has transitioned from smaller-scale operations to securing a high-value, short-cycle contract from a major domestic FMCG player.
Why it mattersFor a micro-cap company, this order provides significant revenue visibility and demonstrates the capability to meet the standards of large-scale FMCG clients, potentially leading to repeat business.
Order Value: ₹526.84 LakhsExecution Period: 45 DaysOrder vs TTM Revenue: ~16.5%TTM Revenue: ₹32 CrMarket Cap: ₹84 Cr
📅 Short termThe stock may see positive momentum as the market reacts to a material order win that will be fully reflected in the financials within the next two months.
📈 Long termIf this leads to a sustained relationship with large FMCG clients, it could structurally improve the company's scale and capacity utilization over the coming years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Tight execution window of 45 days
- Client concentration risk as the name is not disclosed
- Historically low operating margins of 7.6%
Key Highlights
Received a domestic order valued at ₹526.84 Lakhs for skincare products.
Order execution timeline is strictly set at 45 days.
Order value represents ~16.5% of the company's TTM revenue of ₹32 Cr.
Contract awarded by one of India's largest FMCG companies (name withheld).
Focus of the order is specifically on the supply of Face Care Products.
👀 What to Watch
Investors should monitor the September 2026 quarterly results to verify the successful execution of this order and its impact on operating margins, which stood at 7.6% in FY26.
Rs 76.40 Lakh Sample Order from Leading FMCG Group for Skincare Products
Veerhealth Care has secured a sample order worth Rs 76.40 lakhs from a prominent 125-year-old Indian FMCG group for skincare products. While the order is small at approximately 2.4% of TTM revenue, it is strategically significant as it involves a new MRP structure for brand promotion and market expansion. The company has also issued aggressive forward guidance, targeting a revenue of Rs 105 crore in FY27, which is more than 3x its current TTM revenue of Rs 32 crore. Execution of this specific order is expected within 45 days.
Confidence: HIGH
What changedVeerhealth Care has initiated a supply relationship with a major FMCG group and provided specific multi-year financial targets for the first time.
Why it mattersThe association with a large FMCG group validates the company's manufacturing quality; however, the aggressive guidance (3x revenue growth by FY27) sets a high bar for execution that will determine future valuation.
Order Value: Rs 76.40 lakhsOrder vs TTM Revenue: 2.39%Execution Timeline: 45 daysFY27 Revenue Guidance: Rs 105 croreFY28 Revenue Guidance: Rs 156 crore
📅 Short termThe news is likely to be viewed positively by the market due to the pedigree of the client and the high growth projections, potentially supporting the recent momentum in the stock.
📈 Long termThe long-term outlook depends entirely on the company's ability to scale from Rs 32 crore to Rs 105 crore in revenue by FY27 while improving its currently low OPM of 7.6%.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High P/E ratio of 152.2 indicates significant growth is already priced in
- Relatively low promoter holding at 31.5%
- Execution risk in meeting aggressive 3x revenue growth targets
Key Highlights
Received a new sample order worth Rs 76.40 lakhs for skincare products from a leading FMCG company.
Order execution timeline set for 45 days from the date of receipt.
Company projected FY27 total income of Rs 105 crore with a minimum PAT of Rs 5-6 crore.
Company projected FY28 total income of Rs 156 crore with a minimum PAT of Rs 9-10 crore.
Reported book value per share for FY26 at Rs 11.46, expected to increase with preferential warrant funds.
👀 What to Watch
Investors should monitor the conversion of this sample order into larger recurring contracts and track quarterly revenue growth against the company's ambitious FY27 target of Rs 105 crore.
Rs 76.40 Lakh Order Win for Skincare Products from Leading FMCG Company
Veerhealth Care has secured a contract manufacturing order worth Rs 76.40 lakhs from a leading domestic FMCG company for skincare products. The order is expected to be executed within a short timeframe of 45 days, contributing to the current quarter's revenue. While the order size is relatively small at approximately 2.4% of the company's TTM revenue of Rs 32 crore, it validates the company's manufacturing capabilities for major brands. The products are intended for a new brand promotion and market expansion initiative by the client.
Confidence: HIGH
What changedThe company has secured a new contract manufacturing client in the skincare segment, specifically for a brand promotion launch.
Why it mattersWhile the immediate financial impact is modest, the association with a leading FMCG player demonstrates the company's manufacturing standards and potential for scaling its contract manufacturing business.
Order Value: Rs 76.40 LakhsExecution Timeline: 45 DaysOrder vs TTM Revenue: ~2.4%TTM Revenue: Rs 32 Cr
📅 Short termThe news is likely to be viewed positively by the market as it shows active business development, though the small order size may limit significant price movement.
📈 Long termLimited structural impact unless this partnership scales into a multi-crore recurring contract or the company secures multiple such clients.
⚠ Risk flags
- Execution risk within the tight 45-day window
- Low margin nature of contract manufacturing
- Client name confidentiality prevents full due diligence
Key Highlights
Order value of Rs 76.40 lakhs for skincare manufacturing
Strict execution timeline of 45 days from the date of the order
Order represents approximately 2.4% of the TTM revenue of Rs 32 crore
Client is a leading domestic FMCG company (name withheld due to confidentiality)
👀 What to Watch
Watch for the successful execution of this order within the 45-day window and whether it leads to repeat or larger-scale orders from the same FMCG client in future quarters.
₹1.11 Cr Repeat Order; Co. Targets ₹105 Cr Revenue in FY27 via ₹20.25 Cr Fundraise
Veerhealth Care has received a repeat order worth ₹1.11 crores for hair and oral care products from a major Indian pharmacy and hospital network, with execution slated within 45 days. The company has issued aggressive financial guidance, targeting a total income of ~₹105 crores in FY27 and ~₹156 crores in FY28. To fund this growth, the company is raising capital through the allotment of 1,00,00,000 convertible warrants at ₹20.25 each. Promoters are demonstrating confidence by subscribing to 45.37% of the total warrant issue.
Confidence: HIGH
What changedThe company secured a repeat contract from a major client and formalized a significant capital raising plan to fund future expansion and meet high-growth revenue targets.
Why it mattersThe repeat order validates the company's product quality with large-scale institutional buyers, while the ₹20.25 crore fundraise provides the necessary liquidity for capacity expansion to reach its ₹100cr+ revenue goals.
Repeat Order Value: ₹1.11 croresFY27 Revenue Guidance: ~₹105 croresWarrant Issue Price: ₹20.25Total Warrants Allotted: 1,00,00,000Execution Timeline: 45 daysBook Value per share (FY26): ₹11.46
📅 Short termThe stock may see positive momentum driven by the order win and the clear, high-growth financial guidance provided for the next two fiscal years.
📈 Long termThe structural outlook depends on the company's ability to execute its expansion plan using warrant proceeds and achieving the projected 5-10x growth in revenue by FY28.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in meeting high-growth revenue targets
- Equity dilution from the conversion of 1 crore warrants
- Reliance on forward-looking management projections
Key Highlights
Received a repeat order worth ₹1.11 crores for Hair Care and Oral Care products from a leading healthcare network.
Projected Total Income of ~₹105 crores for FY 2026-27 with a minimum PAT of ~₹5-6 crores.
Approved allotment of 1,00,00,000 fully convertible warrants at an issue price of ₹20.25 per warrant.
Promoters to contribute 45,37,000 warrants out of the total 1 crore warrants issued.
Order execution is committed within a short timeframe of 45 days.
👀 What to Watch
Monitor the company's ability to scale operations to meet the ambitious ₹105 crore revenue target for FY27 and track the successful conversion of warrants into equity.
